Recent developments center on the Trump administration’s December 2025 executive order directing expedited review, followed by the April 2026 final order that moved FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act, effective April 28. An expedited DEA administrative hearing on the broader proposed rescheduling of all marijuana convened June 29, 2026, and concluded no later than July 15, with an administrative law judge expected to issue recommendations for the DEA Administrator and Acting Attorney General. These steps build on the 2024 notice of proposed rulemaking and align with HHS scientific findings on accepted medical use. Traders monitor the post-hearing timeline for a final agency determination on full rescheduling, any appeals, or further executive or congressional action that could alter the trajectory.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano$791,956 Wol.
September 30
14%
December 31
27%
$791,956 Wol.
September 30
14%
December 31
27%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Rynek otwarty: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...Recent developments center on the Trump administration’s December 2025 executive order directing expedited review, followed by the April 2026 final order that moved FDA-approved marijuana products and state-licensed medical cannabis from Schedule I to Schedule III of the Controlled Substances Act, effective April 28. An expedited DEA administrative hearing on the broader proposed rescheduling of all marijuana convened June 29, 2026, and concluded no later than July 15, with an administrative law judge expected to issue recommendations for the DEA Administrator and Acting Attorney General. These steps build on the 2024 notice of proposed rulemaking and align with HHS scientific findings on accepted medical use. Traders monitor the post-hearing timeline for a final agency determination on full rescheduling, any appeals, or further executive or congressional action that could alter the trajectory.
Eksperymentalne podsumowanie AI odwołujące się do danych Polymarket. To nie jest porada handlowa i nie ma wpływu na rozstrzyganie tego rynku. · Zaktualizowano



Uważaj na linki zewnętrzne.
Uważaj na linki zewnętrzne.
Często zadawane pytania